ES2337758A1 - Pharmaceutical composition for the treatment of andropenia/andropausia (Machine-translation by Google Translate, not legally binding) - Google Patents
Pharmaceutical composition for the treatment of andropenia/andropausia (Machine-translation by Google Translate, not legally binding) Download PDFInfo
- Publication number
- ES2337758A1 ES2337758A1 ES201030083A ES201030083A ES2337758A1 ES 2337758 A1 ES2337758 A1 ES 2337758A1 ES 201030083 A ES201030083 A ES 201030083A ES 201030083 A ES201030083 A ES 201030083A ES 2337758 A1 ES2337758 A1 ES 2337758A1
- Authority
- ES
- Spain
- Prior art keywords
- andropenia
- treatment
- pharmaceutical composition
- translation
- machine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A23L1/302—
-
- A23L1/304—
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Composición farmacéutica para tratamiento de la andropenia/andropausia.Pharmaceutical composition for the treatment of andropenia / andropause.
La presente invención se refiere a mía nueva composición farmacéutica especialmente concebida como tratamiento o como atenuante en la andropenia/andropausia, también denominada "Síndrome de deficiencia androgénica del anciano".The present invention relates to mine new pharmaceutical composition specially designed as a treatment or as an attenuator in andropenia / andropause, also called "Androgenic deficiency syndrome of the elderly".
De forma mas concreta, el objeto de la invención es un método para prevenir y/o tratar los trastornos producidos por la andropenia/andropausia, mediante la administración de suplementos nutricionales, en forma de comprimidos que, tras su administración y absorción oral, mejoren o ayuden a mejorar al sujeto en cuestión, concretamente en los siguientes aspectos:More specifically, the object of the invention It is a method to prevent and / or treat disorders caused by andropenia / andropause, by supplement administration nutritional, in the form of tablets that, after administration and oral absorption, improve or help improve the subject in question, specifically in the following aspects:
- --
- Disminución del estado de fatiga.Decreased state of fatigue.
- --
- Mejora de la vida sexual del paciente.Improvement of the patient's sexual life.
- --
- Mejora de su estado de ánimo.Improvement of your mood.
\vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
La andropenia/andropausia se caracteriza por una disminución de las hormonas sexuales masculinas a partir de cierta edad y, aunque no se encuentre claramente definida como otras patologías similares como es el caso de la menopausia, si presenta una sintomatología bien conocida. Específicamente los síntomas que aparecen causados por una disminución hormonal son los siguientes:Andropenia / andropause is characterized by a decrease in male sex hormones from certain age and, although not clearly defined as others similar pathologies such as menopause, if it presents a well known symptomatology. Specifically the symptoms that appear caused by a hormonal decrease are the following:
- --
- Disminución de la libido o deseo sexual.Decreased libido or desire sexual.
- --
- Reducción de la calidad de las erecciones.Reduction of the quality of erections
- --
- Depresión del estado de ánimo.Depression of mood.
- --
- Fatiga.Fatigue.
\vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
La terapia hormonal sustitutiva masculina no está muy extendida, al contrario de lo que ocurre entre respectiva para las mujeres; sin embargo puede ser de gran ayuda para aquellos hombres que conjuntamente con su médico decidan llevarla a cabo. La terapia hormonal sustitutiva a largo plazo, tiene como finalidad eliminar o amortiguar los síntomas de la andropausia, incrementar las ganas de vivir, mantener el vigor físico y la capacidad intelectual, dándole un especial enfoque a restaurar las funciones sexuales.Male hormone replacement therapy does not It is very widespread, contrary to what happens between respective for the women; however it can be a great help for those men who together with their doctor decide to carry it out. The Long-term replacement hormone therapy, is intended eliminate or cushion the symptoms of andropause, increase the desire to live, maintain physical vigor and ability intellectual, giving a special focus to restore functions sexual.
Kaufman JM et al, mediante el artículo publicado en la revista Endocrine Reviews; 26 (6): 833-876 de 2005 y cuyo título es "The Decline of Androgen Levels in Elderly Men and Its Clinical and Therapeutic Implications" explica como la necesidad de tratamiento mediante terapia sustitutiva y las condiciones que el sujeto ha de cumplir para que sea susceptible de seguir dicho tratamiento.Kaufman JM et al , through the article published in the journal Endocrine Reviews; 26 (6): 833-876 of 2005 and whose title is "The Decline of Androgen Levels in Elderly Men and Its Clinical and Therapeutic Implications" explains how the need for treatment by substitute therapy and the conditions that the subject has to meet for be able to follow such treatment.
Este tratamiento conlleva unos riesgos que quedan claramente definidos en el artículo escrito por Gruenewald DA et al, denominado "Testosterone supplementation therapy for older men: potential benefits and risks" de J Am Geriatr Soc. 2003 Jan; 51(1):101-15; discussion 115.This treatment involves risks that are clearly defined in the article written by Gruenewald DA et al , called "Testosterone supplementation therapy for older men: potential benefits and risks" by J Am Geriatr Soc. 2003 Jan; 51 (1): 101-15; discussion 115.
Mediante estos artículos queda demostrado la necesidad de buscar un tratamiento coadyudante, en algunos casos severos, o principal en casos donde el sujeto no tenga una disminución importante de las hormonas sexuales.Through these articles the need to seek an adjunctive treatment, in some cases severe, or principal in cases where the subject does not have a significant decrease in sex hormones.
\vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
La invención propuesta pretende, no establecer los niveles hormonales, sino que pretende tratar la sintomatología resultante del déficit de testosterona. Los componentes que forman parte de la invención propuesta, junto con el licopeno, tienen una acción antioxidante, la cual minimizará el desgaste fisiológico, ayudando a que el sujeto no se encuentre en un estado de fatiga y/o depresión de ánimo que aparecen en hombre con andropenia/andropausia.The proposed invention aims not to establish hormonal levels, but aims to treat symptomatology resulting from testosterone deficit. The components that form part of the proposed invention, together with lycopene, have a antioxidant action, which will minimize physiological wear, helping the subject is not in a state of fatigue and / or mood depression that appear in men with andropenia / andropause.
Como hemos citado anteriormente, uno de los trastornos relacionados con la andropenia/andropausia es la fatiga. La invención propuesta aporta una serie de nutrientes necesarios, que junto a los nutrientes obtenidos a través de la dieta diaria, ayudan a tratar dicho trastorno que puede ser causado por una disminución de la actividad hormonal o por la edad.As we mentioned above, one of the Andropenia / Andropause related disorders is fatigue. The proposed invention provides a series of necessary nutrients, that together with the nutrients obtained through the daily diet, they help treat such a disorder that can be caused by a decreased hormonal activity or age.
Ya existen otros complementos vitamínicos que se utilizan como aporte nutricional, sin embargo, la invención propuesta está diseñada para aportar las vitaminas, minerales y otros componentes específicos que necesitaría un sujeto que padece andropenia/andropausia.There are already other vitamin supplements that are they use the invention as a nutritional contribution, however proposal is designed to provide vitamins, minerals and other specific components that a subject suffering from would need andropenia / andropause.
De forma mas concreta se trata de una composición, utilizable como un complemento o suplemento nutricional, composición que alberga desde micronutrientes a vitaminas y minerales, en una proporción determinada, para el tratamiento de los trastornos anteriormente citados y relacionados con la andropenia/andropausia.More specifically it is a composition, usable as a supplement or supplement nutritional, composition that houses from micronutrients to vitamins and minerals, in a certain proportion, for the treatment of the aforementioned and related disorders with andropenia / andropause.
Específicamente el citado complemento o suplemento nutricional está destinado a ser consumido en forma de comprimido, con una posología de un comprimido/día y cuya absorción es por vía oral.Specifically the aforementioned complement or Nutritional supplement is intended to be consumed in the form of tablet, with a dosage of one tablet / day and whose absorption It is oral.
Los componentes de la composición farmacéutica y la cantidad de cada uno de ellos que participa en cada comprimido, con rango comprendido entre valores máximos y mínimos, viene detallada en la siguiente tabla:The components of the pharmaceutical composition and the amount of each of them participating in each tablet, with a range between maximum and minimum values, it comes detailed in the following table:
\vskip1.000000\baselineskip\ vskip1.000000 \ baselineskip
\newpage\ newpage
De acuerdo con un ejemplo preferente de realización, en un comprimido de la aludida composición farmacéutica participan los siguientes compuestos en las cantidades que se reflejan y con sus respectivos índices CDR (Cantidad Diaria Recomendada).According to a preferred example of embodiment, in a tablet of said pharmaceutical composition the following compounds participate in the amounts that are reflect and with their respective CDR indices (Daily Amount Recommended)
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201030083A ES2337758B1 (en) | 2010-01-25 | 2010-01-25 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ANDROPENIA / ANDROPAUSIA. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201030083A ES2337758B1 (en) | 2010-01-25 | 2010-01-25 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ANDROPENIA / ANDROPAUSIA. |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2337758A1 true ES2337758A1 (en) | 2010-04-28 |
ES2337758B1 ES2337758B1 (en) | 2011-02-10 |
Family
ID=42102836
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES201030083A Active ES2337758B1 (en) | 2010-01-25 | 2010-01-25 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ANDROPENIA / ANDROPAUSIA. |
Country Status (1)
Country | Link |
---|---|
ES (1) | ES2337758B1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996013179A2 (en) * | 1994-11-01 | 1996-05-09 | The Procter & Gamble Company | Nutrient supplement compositions providing physiologic feedback |
ES2246798T3 (en) * | 2000-05-18 | 2006-03-01 | Q-Mega Healthcare A/S | DIETARY COMPLEMENT UNDERSTANDING VITAMINS, MINERALS AND POLYINSATURATED FATTY ACIDS. |
US7332181B1 (en) * | 2003-09-05 | 2008-02-19 | Glu-Pro, Inc. | Composition for managing diabetes, obesity, and hyperlipidemia and associated methods |
US20080199534A1 (en) * | 2007-02-15 | 2008-08-21 | Wyeth | Stability in vitamin and mineral supplements |
-
2010
- 2010-01-25 ES ES201030083A patent/ES2337758B1/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996013179A2 (en) * | 1994-11-01 | 1996-05-09 | The Procter & Gamble Company | Nutrient supplement compositions providing physiologic feedback |
ES2246798T3 (en) * | 2000-05-18 | 2006-03-01 | Q-Mega Healthcare A/S | DIETARY COMPLEMENT UNDERSTANDING VITAMINS, MINERALS AND POLYINSATURATED FATTY ACIDS. |
US7332181B1 (en) * | 2003-09-05 | 2008-02-19 | Glu-Pro, Inc. | Composition for managing diabetes, obesity, and hyperlipidemia and associated methods |
US20080199534A1 (en) * | 2007-02-15 | 2008-08-21 | Wyeth | Stability in vitamin and mineral supplements |
Also Published As
Publication number | Publication date |
---|---|
ES2337758B1 (en) | 2011-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Marx et al. | Nutritional psychiatry: the present state of the evidence | |
Yannakoulia et al. | Frailty and nutrition: From epidemiological and clinical evidence to potential mechanisms | |
Giustina et al. | Vitamin D in the older population: a consensus statement | |
Balvers et al. | Recommended intakes of vitamin D to optimise health, associated circulating 25-hydroxyvitamin D concentrations, and dosing regimens to treat deficiency: workshop report and overview of current literature | |
Bueno et al. | The importance for growth of dietary intake of calcium and vitamin D | |
Magalhães et al. | N-acetylcysteine for major depressive episodes in bipolar disorder | |
Holick | Evidence-based D-bate on health benefits of vitamin D revisited | |
Zugman et al. | Reduced dorso-lateral prefrontal cortex in treatment resistant schizophrenia | |
Joshi et al. | Vitamin D deficiency in adults | |
RU2014122168A (en) | IMPROVEMENT OF MEMORY IN PATIENTS WITH AN ESTIMATION OF 24-26 SCORES BY THE SHORT SCALE OF THE ASSESSMENT OF THE MENTAL STATUS | |
RU2014135037A (en) | Nutritional supplements for people aged 50 years and over to increase vitality, immunity, eye and bone health | |
De Sire et al. | Nutritional supplementation in hip fracture sarcopenic patients: a narrative review. | |
Owens | Nutritional support to counteract muscle atrophy | |
Mandana et al. | Comparison of the effect of vit E, vitB6, calcium and omega-3 on the treatment of premenstrual syndrome: a clinical randomized trial | |
ES2337758B1 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ANDROPENIA / ANDROPAUSIA. | |
CA2905817A1 (en) | Reducing the risk of autoimmune disease | |
Ranjit et al. | Importance of micronutrients in the oral cavity | |
Businaro | Food supplements to complement brain functioning. The benefits of a combination of magnesium, folic acid, omega-3 fatty acids and vitamin E | |
Stefańska et al. | Does the usual dietary intake of schizophrenia patients require supplementation with vitamins and minerals | |
Muss et al. | Neuroprotective impact of a vitamin trace element composition-a randomized, double blind, placebo controlled clinical trial with healthy volunteers | |
Johnson | Vitamin K prophylaxis in the newborn: indications and controversies | |
Ruxton et al. | Health impacts of vitamin D: are we getting enough? | |
Strzelecki et al. | Hypomania after augmenting venlafaxine and olanzapine with sarcosine in a patient with schizophrenia: a case study | |
US11065271B2 (en) | Maternal vitamin B12 administration for the prevention of increased adiposity, overweight or obesity in the offspring especially offspring overweight and/or obese mothers | |
Shikino et al. | Vitamin D-deficient osteomalacia due to excessive self-restrictions for atopic dermatitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EC2A | Search report published |
Date of ref document: 20100428 Kind code of ref document: A1 |
|
FG2A | Definitive protection |
Ref document number: 2337758 Country of ref document: ES Kind code of ref document: B1 Effective date: 20110131 |